CRP and chronic obstructive pulmonary disease: In conclusion, in this randomised controlled trial conducted in non-diabetic patients admitted to hospital for COPD exacerbations, who were prone to elevated blood glucose concentrations, metformin had no detectable anti-hyperglycaemic effect and did not significantly alter CRP or clinical end points, although these secondary end points were not powered.